Cargando…
Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906642/ https://www.ncbi.nlm.nih.gov/pubmed/33617776 http://dx.doi.org/10.1016/S0140-6736(21)00357-3 |
| _version_ | 1783655332804820992 |
|---|---|
| author | Sisa, Ivan Noblecilla, Estefania Orozco, Fadya |
| author_facet | Sisa, Ivan Noblecilla, Estefania Orozco, Fadya |
| author_sort | Sisa, Ivan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7906642 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79066422021-02-26 Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs Sisa, Ivan Noblecilla, Estefania Orozco, Fadya Lancet Correspondence Elsevier Ltd. 2021 2021-02-19 /pmc/articles/PMC7906642/ /pubmed/33617776 http://dx.doi.org/10.1016/S0140-6736(21)00357-3 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Sisa, Ivan Noblecilla, Estefania Orozco, Fadya Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs |
| title | Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs |
| title_full | Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs |
| title_fullStr | Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs |
| title_full_unstemmed | Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs |
| title_short | Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs |
| title_sort | rationale to continue approving placebo-controlled covid-19 vaccine trials in lmics |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906642/ https://www.ncbi.nlm.nih.gov/pubmed/33617776 http://dx.doi.org/10.1016/S0140-6736(21)00357-3 |
| work_keys_str_mv | AT sisaivan rationaletocontinueapprovingplacebocontrolledcovid19vaccinetrialsinlmics AT noblecillaestefania rationaletocontinueapprovingplacebocontrolledcovid19vaccinetrialsinlmics AT orozcofadya rationaletocontinueapprovingplacebocontrolledcovid19vaccinetrialsinlmics |